You just read:

EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union

News provided by

Regeneron Pharmaceuticals, Inc.

Jan 23, 2015, 07:32 ET